The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,412,430 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona. The grant will support a 5-year research effort to investigate the use of pharmacological control of the protease-activated receptor-2 (PAR2) as a novel therapeutic strategy for treating asthma. The project aims to uncover the mechanistic roles of epithelial and neuronal PAR2 signaling in allergic asthma, utilizing a combination of in vitro and in vivo models to evaluate the impact of PAR2 modulation on airway cells and sensory neurons. This research is expected to provide a better understanding of PAR2 as a target for developing new asthma drugs and advance the University of Arizona's expertise in this area of biomedical research. The grant was awarded on July 16, 2024 and is scheduled for completion by May 31, 2029.
Generated 1/28/25, 7:57 AM